'Forever chemical' found in dozens of UK rivers, study finds
Researchers say trifluoroacetic acid (TFA), which can take hundreds of years to break down, was detected at 98% of the 54 sites they investigated.
According to the study, one sample - taken from the River Kelvin in Glasgow - contained the second-highest value of TFA ever recorded in surface water globally.
The researchers say the average concentrations of TFA in the UK are at the "higher end" of the global scale compared with the results obtained from other studies - and that the chemical has been found in 31 of the 32 rivers analysed.
The research - funded by environmental charity Fidra and carried out by the University of York - looked at how much TFA was present in surface water.
It marks the first time such a project has been carried out in the UK.
TFA is a type of per- and polyfluoroalkyl substance (PFAS) - also known as "forever chemicals" - found in pesticides, pharmaceuticals and fluorinated gases (F-gases).
But there is "growing concern" about the general impact on human health and its potential risks to drinking water supplies.
According to Fidra, TFA is thought to have "low to moderate" toxicity; however, because levels are rapidly rising in the environment, there are concerns about future impacts.
Studies have linked TFA exposure to birth defects in rabbits, while similar short-chained PFAS have been shown to have toxic effects on freshwater organisms.
The German Federal Environment Agency (UBA) has applied to the European Chemicals Agency (ECHA) for TFA to be classified as toxic for reproduction.
However, its impacts are still being researched.
'Increasingly concerned'
Experts say the results of the latest study provide "compelling evidence of the presence of TFA and PFAS in UK waterways".
The researchers added: "These data should be further analysed to try and establish the drivers of TFA contamination in UK surface waters and routes for source control should be prioritised.
"The scientific communities are becoming increasingly concerned about the potentially harmful properties of TFA and increasing levels in the environment, particularly in water sources.
"There are currently no practical or economically viable ways to remove TFA from water supplies.
"TFA was found in 31 of the 32 rivers examined."
Samples were taken from sites across northern England, Wales, Scotland, and Northern Ireland.
Scientists say TFA has the potential to cause reproductive and liver issues in mammals and is harmful to aquatic life.
It also accumulates in crops and fields and "builds up" in drinking water.
The research comes as a committee of MPs said the UK's water sector is in need of "root-and-branch reform".
The cross-party Environment, Food and Rural Affairs (DEFRA) committee said the industry is "failing" - and trust and accountability in the sector was "very low".
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
I was cured of one of the deadliest forms of cancer after trialling a new drug... my brain cancer is gone
A father who suffered with the world's deadliest form of brain cancer has been cleared after he underwent an experimental treatment. Ben Trotman, 43, who was diagnosed with glioblastoma in October 2022, is now showing no signs of the disease after being administered an immunotherapy drug in a world first two years ago. Most patients with the aggressive form of brain cancer typically die within 12-to-18 months. Consultant medical oncologist, Dr Paul Mulholland, who is leading the new trial and treated Mr Trotman, said: 'It is very unusual to have a clear scan with glioblastoma, especially when he didn't have the follow-up surgery that had been planned to remove all of the tumour that was initially visible on scans. 'We hope that the immunotherapy and follow-up treatment Ben has had will hold his tumour at bay – and it has so far, which we are delighted to see.' Mr Trotman married his wife Emily two months after the immunotherapy treatment in 2023, and in April, his daughter Mabel was born. The father-of-one said: 'Getting this diagnosis was the most traumatic experience. We were grappling with the fact that Ben had gone from being apparently perfectly healthy to having months to live. 'Had we not met Dr Mulholland, that would have been it for us. We felt we had a lucky break in an otherwise devastating situation.' Ben Trotman, 43, who was diagnosed with glioblastoma in October 2022, is now showing no signs of the disease after being administered an immunotherapy drug in a world first two years ago Mr Trotman went on to have the current standard treatment of radiotherapy and chemotherapy. He also undergoes quarterly cans, which continue to return clear. 'We obviously don't know what the future holds but having had the immunotherapy treatment and getting these encouraging scan results has given Emily and I a bit of hope,' he said. 'We are focused on rebuilding the life we thought we had lost and enjoying being parents'. The trial, from University College London Hospital's National Hospital for Neurology and Neurosurgery, follows a previous one on the same drug which closed because of lack of recruitment. But Dame Siobhain McDonagh MP lead a fundraising campaign to raise more than £1million to cover the costs of the new trials after her sister, Baroness McDonagh, died from glioblastoma in 2023. Dame Siobhain said: 'My beloved sister Margaret was appalled to discover that there had been no advances in brain cancer treatment for decades when she was diagnosed with glioblastoma. 'Changing this was Margaret's final campaign and one that I have continued in her memory. 'I am so grateful to the many people who knew and respected Margaret who have come together and helped to raise funds and campaign for this new trial that we are calling Margaret's Trial.' Dr Paul Mulholland said: 'When I met Margaret she said to me 'what can I do to support you to cure this disease?'. 'I am incredibly grateful to her and to Siobhain whose campaigning and fundraising in her sister's memory has led to this new clinical trial opening for patients with this most aggressive form of brain cancer that has such a poor prognosis, with most patients surviving just nine months after diagnosis. 'The crucial element of this trial is that patients will have their immune system boosted by the drug before they have any other treatment, when they are fit and well enough to tolerate the immunotherapy. 'We're taking everything we have learned from previous trials into this new study and we are already planning follow-on trials. 'My aim is to find a cure for glioblastoma.' The National Brain Appeal is currently funding two posts in support of Dr Mulholland's research. Treatment will take place at the NIHR UCLH's Clinical Research Facility and at the National Hospital for Neurology and Neurosurgery.
Daily Mail
an hour ago
- Daily Mail
Diet that sheds weight fast by eating MORE: This easy plan was made to help cancer patients - then doctors realised its amazing benefits. JANE ALEXANDER tried it and couldn't believe how much she lost...
At the age of 65, I have reached crunch point. I'm sick to the back teeth of weird diets and I'm seriously fed up with feeling hungry. I'm also really hacked off at still being fat. It's not just how I look – my GP has told me I really need to lose my stores of visceral fat (the pernicious fat around the organs in the abdomen that is so bad for our health).
The Independent
2 hours ago
- The Independent
New AI tool could speed up skin cancer diagnoses in remote parts of world
A researcher at a Scottish university has developed AI tools that could give people in remote areas of the world access to fast and potentially life-saving skin cancer diagnoses. Tess Watt, the PhD student at Heriot-Watt University in Edinburgh who led the project to develop the technology, said it is intended to enable early detection of skin conditions anywhere in the world, and without the need for direct access to dermatologists. The technology also works without internet access. The system involves a patient taking a photograph of their skin complaint using a small camera attached to a Raspberry Pi device – a cheap, energy-efficient handheld computer that is capable of storing vast amounts of information. The photograph is analysed in real-time using the latest state-of-the-art image classification, comparing it to an enormous dataset of thousands of images stored on the device to reach a diagnosis. The findings are then shared with a local GP service to begin a suitable treatment plan. The project is understood to be the first of its kind to combine AI medical diagnosis with the aim of serving remote communities. Ms Watt explained: ' Healthcare from home is a really important topic at the moment, especially as GP wait times continue to grow. 'If we can empower people to monitor skin conditions from their own homes using AI, we can dramatically reduce delays in diagnosis.' A prototype of the device has already been demonstrated at Heriot-Watt's advanced health and care technologies suite. The research team said the tool is up to 85% accurate in its diagnostic capabilities, but they hope to increase this further by gaining access to more skin lesion datasets, aided by advanced machine tools. Ms Watt is also in talks with NHS Scotland to begin the ethical approval process for testing the technology in real-world clinical settings. 'Hopefully in the next year or two, we'll have a pilot project under way,' she said, noting medical technology often takes years to move from prototype to implementation. She added: 'By the time I finish my PhD, three years from now, I'd love to see something well into the pipeline that's on its way to real-world use.' The university said the long-term vision is to roll the system out first across remote regions of Scotland, before expanding to global areas with limited access to dermatological care. It added the technology could also offer vital support to patients who are infirm or unable to travel, allowing loved ones to assist with capturing and submitting diagnostic images to GPs. Ms Watt's academic supervisor, Dr Christos Chrysoulas, said: 'E-health devices must be engineered to operate independently of external connectivity to ensure continuity of patient service and safety. 'In the event of a network or cloud service failure, such devices must fail safely and maintain all essential clinical operations without functional degradation. 'While auxiliary or non-critical features may become temporarily unavailable, the core diagnostic and even therapeutic capabilities must remain fully operational, in compliance of course with safety and regulatory requirements. 'Ensuring this level of resilience in affordable, low-cost medical devices is the essence of our research, particularly for deployment in resource-limited settings and areas with limited or no connectivity, where uninterrupted patient care must still be guaranteed.' UK Science and Technology Secretary Peter Kyle commented on the research, saying: 'Low-cost technology which could help detect skin cancer early and at home, without even the need for internet access, is an incredible example of AI's potential to break down barriers in healthcare and save lives. 'Promising, first of its kind research like this also demonstrates the crucial role UK innovators can play in improving the lives of people of all backgrounds, wherever they live, and makes clear the value of government investing in research to deliver our plan for change.'
